» Articles » PMID: 38141133

Prevalence and Type of MMR Expression Heterogeneity in Colorectal Adenocarcinoma: Therapeutic Implications and Reporting

Abstract

Mismatch repair (MMR) immunohistochemical (IHC) evaluation has entered pathology routine practice as the first-line screening method to identify patients with MMR deficient (MMRd)/microsatellite instability (MSI) colorectal cancer (CRC), and its misdiagnosis may significantly impact the personalization of CRC patient care. To determine the prevalence of MMR protein intratumor heterogeneity in real-world practice, we collected a series of 8282 CRCs tested for MMR proteins in the setting of Lynch syndrome universal screening. Four heterogenous cases were also investigated for tumor infiltrating lymphocytes count, MSI status, and consensus molecular subtypes by Nanostring nCounter® Platform. Overall, 1056 (12.8%) CRCs showed a MMR altered status, with 46 cases showing a heterogeneous MMR profile (0.56% of the total, and 4.36% of all MMRd cases). To conclude, the authors make some critical remarks regarding the approach to MMR heterogeneity in clinical practice and routine diagnostics.

Citing Articles

Be bold, start cold! cold formalin fixation of colorectal cancer specimens granted superior DNA and RNA quality for downstream molecular analysis.

Nano E, Gambella A, Paudice M, Garuti A, Pigozzi S, Valle L Histochem Cell Biol. 2024; 162(6):541-550.

PMID: 39317804 PMC: 11455702. DOI: 10.1007/s00418-024-02326-5.

References
1.
Fassan M, Scarpa A, Remo A, De Maglio G, Troncone G, Marchetti A . Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. Pathologica. 2020; 112(3):248-259. PMC: 7931577. DOI: 10.32074/1591-951X-158. View

2.
McCarthy A, Capo-Chichi J, Spence T, Grenier S, Stockley T, Kamel-Reid S . Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res. 2018; 5(2):115-129. PMC: 6463865. DOI: 10.1002/cjp2.120. View

3.
Westwood A, Glover A, Hutchins G, Young C, Brockmoeller S, Robinson R . Additional loss of MSH2 and MSH6 expression in sporadic deficient mismatch repair colorectal cancer due to MLH1 promoter hypermethylation. J Clin Pathol. 2019; 72(6):443-447. DOI: 10.1136/jclinpath-2018-205687. View

4.
Tachon G, Frouin E, Karayan-Tapon L, Auriault M, Godet J, Moulin V . Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. Eur J Cancer. 2018; 95:112-116. DOI: 10.1016/j.ejca.2018.01.087. View

5.
Loupakis F, Maddalena G, Depetris I, Murgioni S, Bergamo F, Dei Tos A . Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. J Immunother Cancer. 2019; 7(1):297. PMC: 6842181. DOI: 10.1186/s40425-019-0788-5. View